Cabozantinib (XL184) in Men With Castrate-Resistant Prostate Cancer
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
Cabozantinib (XL184) is a new drug that is being developed to treat cancer. Cabozantinib
works by blocking the "angiogenesis," or the growth of new blood vessels, to the tumor. This
is similar to how several other cancer drugs work but in addition Cabozantinib also blocks
other pathways that may be responsible for allowing cancer cells to become resistant to these
other "anti-angiogenic" treatments. So far cabozantinib has been investigated in treating
brain cancer and a rare form of thyroid cancer. This study will explore lower doses of
cabozantinib with the goal to find the most effective, safe, and tolerable dose without
undesirable side effects.